 Shares of Talaris Therapeutics Inc. TALS, -1.63 tumbled 21.5 in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplant recipients died. The patient had been diagnosed with a moderate form of acute graft-vs-host disease. 